We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Agilent Acquires Its Analytic Joint Venture

By Biotechdaily staff writers
Posted on 16 Feb 2006
Print article
Agilent Technologies Inc. (Palo Alto, CA, USA), and Yokogawa Electric Corp. (Tokyo, Japan) have announced that their joint venture, Yokogawa Analytical Systems, became a wholly owned Agilent subsidiary on February 1, 2006.

Yokogawa Analytical Systems was founded as a joint venture by Agilent and Yokogawa Electric in 1992. The company designed and produced measurement and control and industrial automation systems, including inductively coupled plasma mass spectrometry (ICP/MS) systems, which are analytic systems used in gas chromatography for laboratory and other scientific applications. Agilent and Yokogawa noted that the joint venture achieved its original objectives.

Agilent decided that it is the right time for Yokogawa Analytical Systems to become a wholly owned subsidiary in order to expand the market presence for its products and services in Japan. By selling its stake in the joint venture, Yokogawa Electric will be able to dedicate additional resources to its core businesses. The firm is receiving approximately U.S.$106 million for the transaction, including $98 million from Agilent for its 49% share in the joint venture, and $7.5 million in dividends from Yokogawa Analytical Systems.

Yokogawa Electric was founded in 1915 and is engaged in research and innovation. Its core businesses are industrial automation and control, test and measurement, information systems, and industry support.

"Yokogawa and Agilent have had a very strong, cooperative relationship over the past 13 years,” said Ryuji Kanno, president, Yokogawa Analytical Systems. "This acquisition of Yokogawa's minority share is a positive step for both companies.”



Related Links:
Agilent
Yokogawa
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.